Early treatment for high-risk CCUS
Part of Blood & lymphatic clinical trials.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had low blood counts (low red blood cells, white blood cells, or platelets) for at least 4 months.
- You have a specific gene mutation (called a pathogenic variant) found in a blood or bone marrow test.
- You have a high risk score based on a special calculator for clonal hematopoiesis.
- You do not have a current blood cancer or other cancer that needs strong treatment.
- Your liver and kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
This trial tests a new approach to slow or stop the growth of abnormal blood stem cells in people at high risk for developing blood cancers. It is for older adults with low blood counts and specific genetic changes in their blood cells.
Hear when a new Clonal Cytopenia of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.